Pregnant women with low risk indicators for fetal chromosomal aneuploidy will be enrolled.
Study blood will be collected in the first or second trimester at a scheduled prenatal
screening visit, processed to plasma, and stored frozen until analysis. Each pregnancy will
be followed until delivery and the birth outcome recorded.